ESTRO 2025 - Abstract Book

S125

Invited Speaker

ESTRO 2025

4858

Speaker Abstracts Metastasis-directed therapy with or without systemic therapy for high-risk BCR Piet Ost Department of radiation oncology, Iridium Network, Antwerp, Belgium

Abstract: Background: Oligo-recurrent hormone-sensitive prostate cancer (or-HSPC) signifies limited-site recurrence after primary curative therapy, presenting as nodal or distant disease. Advances in imaging, particularly PSMA-PET, allow earlier detection at biochemical recurrence (BCR). Metastasis-directed therapy (MDT), targeting these limited recurrences, is an evolving strategy aiming to delay systemic treatments like androgen deprivation therapy (ADT) and potentially improve outcomes. MDT can be used either alone or augmented with systemic therapies. This talk